Next Article in Journal
A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring
Previous Article in Journal
An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
Perspective

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

1
Division of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada
2
Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
3
Division of Gynecologic Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada
4
Department of Obstetrics Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada
5
Division of Gynecologic Oncology, Princess Margaret Cancer Center, University Health Network, Sinai Health System, Toronto, ON M5B 2M9, Canada
6
Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1X8, Canada
7
Department of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada
8
Department of Gynecological Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada
9
Division of Gynecologic Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
10
Institut du Cancer de Montréal, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC H2X 0A9, Canada
11
Division of Gynecologic Oncology, Université de Montréal, Montreal, QC H3T 1J4, Canada
12
Department of Obstetrics and Gynecology, McGill University Jewish General Hospital, Montreal, QC H3T 1E2, Canada
13
IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada
14
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(6), 4354-4369; https://doi.org/10.3390/curroncol29060348
Received: 2 May 2022 / Revised: 26 May 2022 / Accepted: 27 May 2022 / Published: 17 June 2022
(This article belongs to the Section Gynecologic Oncology)
The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP) inhibitors have been established as a standard of care maintenance therapy to prolong remission and prevent relapse following a response to first-line platinum-chemotherapy. Olaparib and niraparib are the PARP inhibitors currently approved for use in the first-line maintenance setting in Canada. Selection of maintenance therapy requires consideration of patient and tumour factors, presence of germline and somatic mutations, expected drug toxicity profile, and treatment access. This paper discusses the current clinical evidence for first-line PARP inhibitor maintenance therapy in patients with advanced, high-grade EOC and presents consensus statements and a treatment algorithm to aid Canadian oncologists on the selection and use of PARP inhibitors within the Canadian EOC treatment landscape. View Full-Text
Keywords: epithelial ovarian cancer; PARP inhibitors; BRCA; homologous recombination repair epithelial ovarian cancer; PARP inhibitors; BRCA; homologous recombination repair
Show Figures

Figure 1

MDPI and ACS Style

Tinker, A.V.; Altman, A.D.; Bernardini, M.Q.; Ghatage, P.; Gien, L.T.; Provencher, D.; Salvador, S.; Doucette, S.; Oza, A.M. A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Curr. Oncol. 2022, 29, 4354-4369. https://doi.org/10.3390/curroncol29060348

AMA Style

Tinker AV, Altman AD, Bernardini MQ, Ghatage P, Gien LT, Provencher D, Salvador S, Doucette S, Oza AM. A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology. 2022; 29(6):4354-4369. https://doi.org/10.3390/curroncol29060348

Chicago/Turabian Style

Tinker, Anna V., Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, and Amit M. Oza. 2022. "A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers" Current Oncology 29, no. 6: 4354-4369. https://doi.org/10.3390/curroncol29060348

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop